Avanos Medical (AVNS) Research & Development (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Research & Development data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 3.7% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $23.1 million (down 6.1% YoY), and the FY2025 full-year result was $23.3 million, down 11.07% from the prior year.
• Research & Development retreated to $5.2 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.8 million in Q1 2022 to a low of $5.2 million in Q1 2026.
• A 5-year average of $6.6 million and a median of $6.8 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development gained 22.03% in 2022 and slipped 22.86% in 2025, its largest moves.
• Tracing AVNS's Research & Development over 5 years: stood at $7.2 million in 2022, then retreated by 5.56% to $6.8 million in 2023, then slipped by 16.18% to $5.7 million in 2024, then climbed by 7.02% to $6.1 million in 2025, then fell by 14.75% to $5.2 million in 2026.
• Business Quant data shows AVNS's Research & Development at $5.2 million in Q1 2026, $6.1 million in Q4 2025, and $6.0 million in Q3 2025.